OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

OSTX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

OS Therapies IncorporatedAMEX: OSTX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 30783.5% from a year ago

Cash & equivalents stood at $917.55M at the end of Q1 FY2026, up 30783.5% from a year earlier and up 240.0% from the prior quarter. Over 3 fiscal years it compounded at +1063.1% a year.

Context

  • Cash & equivalents amounted to 12570.5% of total assets at the end of Q1 FY2026, up 12500.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +30783.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$917.55M+240.0% QoQ
Last fiscal yearDec 2025
$269.83M+4776.3% YoY
Year agoMar 2025
$2.97M+30783.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30783.5%——
1 year+4776.3%——
3-year CAGR+1063.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
269.83M USD
Year-over-year change
+4776.3%
4-year CAGR
+660.2%

Cash & Equivalents vs competitors

How OSTX compares with its peers on the latest reported figures

  • OSTX's Mar 2026 cash & equivalents of $917.55M is the highest of the 9 companies compared; the peer median is $15.76M.
  • Its year-over-year change of +30783.5% is the highest of 9, against a peer median of +21.5%.
  • Cash & equivalents amounts to 12570.5% of total assets for OSTX, versus a peer median of 91.4%.
OSTX Competitors Peer median
Cash & Equivalents for OSTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$917.55M +30783.5%+1063.1%12570.5%
ADAGAdagene Inc.Dec 2025$74.52M -12.5%-19.7%95.2%
EQEquillium, Inc.Mar 2026$61.32M +322.9%-20.0%97.2%
SPRBSpruce Biosciences, Inc.Mar 2026$54.08M +111.1%+25.9%96.3%
HOWLWerewolf Therapeutics, Inc.Jun 2026$21.99M -71.7%-23.5%91.0%
INKTMiNK Therapeutics, Inc.Mar 2026$9.53M +194.5%-12.0%91.8%
OTLKOutlook Therapeutics, Inc.Mar 2026$7.75M +2.5%-22.5%35.4%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$6.71M +21.0%-27.0%56.4%
COEPCoeptis Therapeutics, Inc.Mar 2026$5.21M +22.1%+14.4%26.3%
Peer median (excluding OSTX) $15.76M+21.5%-19.8%91.4%

Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents80.79K171.48K38.98K5.53M269.83M
Short-term Investments00000
Net Receivables231.07K1.15K000
Inventory00000
Other Current Assets956K324.21K751.05K0(269.56M)
Total Current Assets312.82K496.84K790.03K5.53M332.91K
Property, Plant & Equipment (Net)13.08K12.27K8.05K5.27K2.49M
Goodwill00000
Intangible Assets00006.5M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets000(0)(2.49M)
Total Non-current Assets13.08K12.27K8.05K5.27K6.51M
Total Assets325.89K509.11K798.08K5.54M6.84M
Account Payables856.52K1.23M2.72M1.66M9.94M
Short-term Debt0014.61M00
Tax Payables367.02K426.01K000
Deferred Revenue00000
Other Current Liabilities1.61M3.04M4.71M2.35M0
Total Current Liabilities3.5M6.15M24.71M4.63M11.76M
Long-term Debt7.07M10.35M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)100K100K100K0100K
Other Non-current Liabilities1.11M1.47M100K100K1.07M
Total Non-current Liabilities8.28M11.92M100K100K1.17M
Total Liabilities11.78M18.07M24.81M4.73M12.94M
Common Stock9.98K4.99K5.34K20.87K37.12K
Retained Earnings(15.22M)(21.6M)(29.52M)(40.4M)(67.19M)
Accumulated OCI00000
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity(11.45M)(17.56M)(24.02M)811.49K(6.1M)
Total Debt7.07M10.35M14.61M00
Net Debt6.99M10.18M14.57M(5.53M)(269.83M)

OS Therapies Incorporated

AMEX:OSTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.